Clinical Trial Results Presentation Template

Clinical trial results presentations serve multiple high-stakes audiences simultaneously: investors who need to understand the commercial implications, regulatory scientists who need to evaluate the evidence base, Key Opinion Leaders (KOLs) who will influence clinical adoption, and the broader medical community who will ultimately use the treatment. Each audience has different baseline knowledge and different questions. A single presentation cannot serve all four audiences equally — but it can be structured to give each enough to make the decisions they need to make.

This template covers the investor-facing clinical data presentation and the scientific/medical audience presentation, noting where they diverge.

Before the Structure: Key Principles

Statistical significance is not clinical significance. A statistically significant result (p < 0.05) that shows a 1.2-day reduction in hospital stay may not be clinically meaningful. Your presentation must address both — what the data shows statistically and whether the effect size is large enough to change clinical practice.

Regulatory implications must be explicit. For biotech and pharmaceutical companies, clinical data is only valuable insofar as it supports a regulatory approval pathway. Every clinical results presentation should state clearly what the data does and does not support from a regulatory perspective.

Be honest about limitations. Investors, regulators, and KOLs who discover you obscured limitations during diligence or peer review will not trust your next dataset. Proactive disclosure of study limitations is a sign of scientific integrity, not weakness.

---

Investor-Facing Clinical Data Presentation

Investors are evaluating the commercial opportunity and the regulatory risk profile, not the scientific evidence in isolation.

Slide 1: Executive Summary for Investors

• Drug or device name, mechanism of action (one sentence for non-scientists)
• Disease area and indication
• Patient population studied
• Primary endpoint result: did the study meet its primary endpoint? (yes/no, with the actual number)
• Statistical significance of primary endpoint (p-value and confidence interval)
• Regulatory pathway implication: what does this data support in terms of a regulatory submission?

If the study missed its primary endpoint but had significant secondary endpoint results, state this explicitly on slide one. Investors who discover a missed primary endpoint on slide seven will not trust the rest of the presentation.

Slide 2: Study Design

• Trial phase (Phase 1, 2, 2b, 3, or pivotal)
• Study type: randomized controlled trial, open-label, single-arm, adaptive design
• Patient population: N, inclusion/exclusion criteria, disease stage, prior treatment history
• Comparator: placebo, standard of care, or active comparator
• Primary endpoint: definition and measurement methodology
• Key secondary endpoints
• Duration of treatment and follow-up

The study design slide should allow a sophisticated investor to evaluate whether the trial was designed to generate regulatory-grade evidence or exploratory data. A Phase 2 single-arm study with a surrogate endpoint tells a very different regulatory story than a Phase 3 randomized controlled trial with an overall survival endpoint.

Slide 3: Primary Endpoint Results

Present the primary endpoint result with full statistical context.

Include:

• Effect size: the actual difference between treatment and control groups (not just that there was a statistically significant difference)
• Confidence interval: the range within which the true effect is likely to fall with 95% certainty
• P-value
• Clinical meaningfulness: how does this effect size compare to what the field considers a meaningful improvement? Reference the minimum clinically important difference (MCID) if it has been established for this endpoint

Visual format: A Kaplan-Meier survival curve for time-to-event endpoints, a forest plot for subgroup analyses, or a simple bar chart comparing treatment and control for single-measurement endpoints. Choose the visual that most honestly represents the data, not the one that makes the result look most impressive.

Slide 4: Secondary Endpoints and Exploratory Data

Secondary endpoints provide context for the primary result and often contain the data that guides clinical adoption decisions.

For each key secondary endpoint:

• Endpoint definition
• Result (with statistical significance or confidence interval)
• Whether the study was powered for this endpoint (if not, note that this is exploratory)

Patient-reported outcomes: Biotech investors increasingly focus on patient-reported outcome (PRO) data as a measure of clinical meaningfulness and a regulatory differentiator. If your trial included PRO endpoints, present them prominently.

Slide 5: Safety Profile

Safety data is evaluated as carefully as efficacy data — by regulators, by KOLs, and by sophisticated biotech investors who understand that commercial success depends on having a safety profile that physicians will accept.

Present:

• Treatment-emergent adverse events (TEAEs): incidence rate in treatment vs. control groups
• Serious adverse events (SAEs): definition used, rate in treatment vs. control
• Adverse events leading to discontinuation: rate in treatment vs. control
• Deaths (if any): cause and attribution assessment
• Laboratory abnormalities: clinically significant findings
• Any black box warning precursors or regulatory concerns identified

Do not hide safety signals. Regulators will find them. KOLs who prescribe the drug will encounter them. Investors who discover unreported safety signals will lose confidence in management permanently.

Slide 6: Competitive Context

Where does this data position the drug or device relative to existing treatments and other programs in development?

Compare:

• Your primary endpoint result to results from comparable clinical trials in the same indication
• Your safety profile to the comparator class
• Your patient population to populations studied in competing trials (are you comparing to sicker or healthier patients?)

Be honest about where you are differentiated and where you are not. A me-too drug in a crowded indication with a modest efficacy advantage is a commercial risk investors need to understand.

Slide 7: Regulatory and Commercial Pathway

• What regulatory submission does this data support? (NDA, BLA, 510k, PMA, EUA)
• What breakthrough therapy, fast track, or orphan drug designations do you hold, if any?
• What is the expected regulatory timeline from data readout to submission to approval?
• What additional clinical data (if any) is required before submission?
• Market size, pricing assumptions, and peak sales estimate

For early-stage biotechs, the regulatory pathway discussion often determines whether investors characterize the data as a go or no-go for continued investment.

---

Scientific/Medical Audience Presentation

For KOL presentations, medical conferences, or advisory board meetings, the structure shifts from commercial implications to scientific evidence quality.

Key differences from the investor version:

• Lead with the clinical question and unmet need, not with the commercial opportunity
• Include full methodology details: statistical analysis plan, randomization procedure, blinding methods, adjudication committee charter
• Include subgroup analyses with appropriate caveats about pre-specification and statistical power
• Include a longer safety section with individual adverse event tables
• End with implications for clinical practice: what would a physician treating this patient population conclude from this data?

---

Common Clinical Results Presentation Mistakes

Reporting p-values without effect sizes. "Statistically significant (p = 0.03)" without the absolute risk reduction, hazard ratio, or mean difference leaves the audience unable to assess clinical meaningfulness.

Missing confidence intervals. A p-value tells you whether a result is statistically significant. A confidence interval tells you the range of plausible true effects. Both are required for a complete presentation.

Burying the safety data. Placing adverse event tables in the appendix signals that you are de-emphasizing safety. Reviewers will find them anyway.

Comparing to cherry-picked historical controls. Cross-trial comparisons are inherently confounded by differences in patient populations, endpoints, and measurement methodology. If you make them, note the limitations explicitly.

---

slide-deck.io generates clinical trial results presentations with Kaplan-Meier visualizations, adverse event tables, endpoint comparison charts, and regulatory pathway summaries — built for biotech investor meetings, KOL advisory boards, and medical conference presentations. Export to PowerPoint for submission to investment committees or medical review boards.

Create your clinical trial results presentation